Tempus to Buy Cancer Test Maker Personalis for $1.5 Billion

Tempus to buy cancer test-maker Personalis for $1.5B

Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.

Tempus to acquire cancer test maker Personalis for $1.5B

Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.

Tempus AI to acquire Personalis in $1.5B deal; expands MRD cancer testing

Tempus AI (TEM) to buy Personalis (PSNL) for $1.5B, boosting MRD cancer monitoring with NeXT test.

Tempus to buy cancer test maker Personalis for $1.5 billion

Tempus AI to acquire Personalis for $1.5B

Personalis to be Acquired by Tempus AI for $1.9 Billion // Cooley // Global Law Firm